PhaseBio is leveraging our ELP biopolymer technology to evaluate additional preclinical and discovery-stage candidates. Our focus is on proteins and peptides that are scientifically or clinically validated, but where a suboptimal half-life, stability and delivery limit their potential therapeutic applications.

Our more advanced preclinical programs include:

  • C-type natriuretic peptide. C-type natriuretic peptide (CNP) is a regulator of bone growth and can rescue defects in fibroblast growth factor 3 that cause achondroplasia resulting in dwarfism. Native CNP has a half-life of less than three minutes, limiting its use as a direct therapeutic. We are developing our CNP-ELP product candidate to deliver therapeutic levels of CNP with once weekly subcutaneous injections. In a mouse model, we observed a statistically significant effect on linear growth when our CNP-ELP product candidate was injected once every four days.
  • Glucagon-like peptide-2. Glucagon-like peptide-2 (GLP-2) stimulates growth of intestinal villi, increasing their ability to absorb nutrients. GLP-2 is a potential treatment for patients with short bowel syndrome, Crohn’s disease or mucositis in patients undergoing cancer treatment. Teduglutide, currently marketed under the brand name Gattex, is an FDA-approved therapy based on GLP-2 that requires daily injections. In animal models, our GLP-2-ELP product candidate provided sustained levels of GLP-2, resulting in greater efficacy than teduglutide with less frequent dosing.